Department of Molecular Genetics and Microbiology, School of Medicine, Duke University, Durham, North Carolina (T.A., O.F.); Columbia Center for Human Development/Columbia Center for Stem Cell Therapies Department, Columbia University, New York (M.H.-N.); Chemistry Department, School of Math and Science at the United States Naval Academy, Annapolis, Maryland (J.M.G.); Atomwise Inc., San Francisco, California (J.M.G., V.K.); and Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (T.K.)
Department of Molecular Genetics and Microbiology, School of Medicine, Duke University, Durham, North Carolina (T.A., O.F.); Columbia Center for Human Development/Columbia Center for Stem Cell Therapies Department, Columbia University, New York (M.H.-N.); Chemistry Department, School of Math and Science at the United States Naval Academy, Annapolis, Maryland (J.M.G.); Atomwise Inc., San Francisco, California (J.M.G., V.K.); and Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (T.K.).
Mol Pharmacol. 2024 Jun 18;106(1):21-32. doi: 10.1124/molpharm.123.000843.
Olfactory receptors are members of class A (rhodopsin-like) family of G protein-coupled receptors (GPCRs). Their expression and function have been increasingly studied in nonolfactory tissues, and many have been identified as potential therapeutic targets. In this manuscript, we focus on the discovery of novel ligands for the olfactory receptor family 51 subfamily E2 (OR51E2). We performed an artificial intelligence-based virtual drug screen of a ∼2.2 million small molecule library. Cell-based functional assay identified compound 80 (C80) as an antagonist and inverse agonist, and detailed pharmacological analysis revealed C80 acts as a negative allosteric modulator by significantly decreasing the agonist efficacy, while having a minimal effect on receptor affinity for agonist. C80 binds to an allosteric binding site formed by a network of nine residues localized in the intracellular parts of transmembrane domains 3, 5, 6, 7, and H8, which also partially overlaps with a G protein binding site. Mutational experiments of residues involved in C80 binding uncovered the significance of the C240 position in blocking the activation-related conformational change and keeping the receptor in the inactive form. Our study provides a mechanistic understanding of the negative allosteric action of C80 on agonist-ctivated OR51E2. We believe the identification of the antagonist of OR51E2 will enable a multitude of studies aiming to determine the functional role of this receptor in specific biologic processes. SIGNIFICANCE STATEMENT: OR51E2 has been implicated in various biological processes, and its antagonists that can effectively modulate its activity have therapeutic potential. Here we report the discovery of a negative allosteric modulator of OR51E2 and provide a mechanistic understanding of its action. We demonstrate that this modulator has an inhibitory effect on the efficacy of the agonist for the receptor and reveal a network of nine residues that constitute its binding pocket, which also partially overlaps with the G protein binding site.
嗅觉受体是 G 蛋白偶联受体 (GPCR) 中 A 类 (视紫红质样) 家族的成员。它们在非嗅觉组织中的表达和功能已经得到越来越多的研究,许多嗅觉受体已被确定为潜在的治疗靶点。在本文中,我们专注于发现嗅觉受体 51 亚家族 E2(OR51E2)的新型配体。我们对大约 220 万个小分子文库进行了基于人工智能的虚拟药物筛选。基于细胞的功能测定鉴定出化合物 80(C80)为拮抗剂和反向激动剂,详细的药理学分析表明 C80 通过显著降低激动剂效力作为负变构调节剂起作用,而对激动剂与受体的亲和力影响很小。C80 结合到由位于跨膜域 3、5、6、7 和 H8 的细胞内部分的九个残基组成的变构结合位点,该位点也部分与 G 蛋白结合位点重叠。涉及 C80 结合的残基的突变实验揭示了 C240 位置在阻止激活相关构象变化和使受体保持非活性形式方面的重要性。我们的研究提供了对 C80 对激动剂激活的 OR51E2 的负变构作用的机制理解。我们相信 OR51E2 拮抗剂的鉴定将能够进行多种研究,旨在确定该受体在特定生物过程中的功能作用。
OR51E2 已被牵连到各种生物过程中,其能够有效调节其活性的拮抗剂具有治疗潜力。在这里,我们报告了 OR51E2 的负变构调节剂的发现,并提供了其作用的机制理解。我们证明该调节剂对受体激动剂的效力具有抑制作用,并揭示了构成其结合口袋的九个残基网络,该网络也部分与 G 蛋白结合位点重叠。